Sam Chun Dang Pharm. Co. Ltd Total Assets
Sam Chun Dang Pharm. Co. Ltd total assets. Based on the latest financial reports, Sam Chun Dang Pharm. Co. Ltd (000250) holds total assets worth ₩575.39 Billion KRW (≈ $389.93 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Sam Chun Dang Pharm. Co. Ltd market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Sam Chun Dang Pharm. Co. Ltd (2012–2025)
Total assets of Sam Chun Dang Pharm. Co. Ltd from 2012 to 2025. This chart illustrates how Sam Chun Dang Pharm. Co. Ltd's total assets have evolved over time, based on quarterly financial data. See Sam Chun Dang Pharm. Co. Ltd share price for real-time trading data and today's change.
Sam Chun Dang Pharm. Co. Ltd - Asset Composition Analysis
Sam Chun Dang Pharm. Co. Ltd Total Assets Breakdown (December 2025)
Sam Chun Dang Pharm. Co. Ltd total assets breakdown as of December 2025. Sam Chun Dang Pharm. Co. Ltd's total assets of ₩575.39 Billion consist of 43.1% current assets and 56.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 17.1% |
| Accounts Receivable | ₩45.58 Billion | 8.1% |
| Inventory | ₩52.61 Billion | 9.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩126.01 Billion | 22.5% |
| Goodwill | ₩3.75 Billion | 0.7% |
Asset Composition Trend (2012–2025)
This chart illustrates how Sam Chun Dang Pharm. Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Sam Chun Dang Pharm. Co. Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sam Chun Dang Pharm. Co. Ltd's current assets represent 43.1% of total assets in 2025, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 17.1% of total assets in 2025, up from 5.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 6.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 22.5% of total assets.
Sam Chun Dang Pharm. Co. Ltd Competitors by Total Assets
Key competitors of Sam Chun Dang Pharm. Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
BINEX Co. Ltd
KQ:053030
|
Korea | ₩304.35 Billion |
|
TegoScience Inc
KQ:191420
|
Korea | ₩76.38 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩267.18 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩125.25 Billion |
|
Komipharm International Co. Ltd
KQ:041960
|
Korea | ₩133.92 Billion |
|
Aprogen Healthcare & Games Inc
KQ:109960
|
Korea | ₩324.89 Billion |
Sam Chun Dang Pharm. Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.94 | 3.34 |
| Quick Ratio | 1.66 | 2.26 | 2.83 |
| Cash Ratio | 0.00 | 0.00 | 1.23 |
| Working Capital | ₩126.85 Billion | ₩132.79 Billion | ₩120.66 Billion |
Sam Chun Dang Pharm. Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Sam Chun Dang Pharm. Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.94 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.0% |
| Total Assets | ₩561.23 Billion |
| Market Capitalization | $2.60 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sam Chun Dang Pharm. Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sam Chun Dang Pharm. Co. Ltd's assets grew by 8.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sam Chun Dang Pharm. Co. Ltd (2012–2025)
The table below shows the annual total assets of Sam Chun Dang Pharm. Co. Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩561.23 Billion ≈ $380.34 Million |
+7.98% |
| 2024-12-31 | ₩519.77 Billion ≈ $352.24 Million |
+27.39% |
| 2023-12-31 | ₩408.02 Billion ≈ $276.51 Million |
+9.45% |
| 2022-12-31 | ₩372.79 Billion ≈ $252.64 Million |
+7.74% |
| 2021-12-31 | ₩346.00 Billion ≈ $234.48 Million |
+9.12% |
| 2020-12-31 | ₩317.08 Billion ≈ $214.88 Million |
+9.28% |
| 2019-12-31 | ₩290.15 Billion ≈ $196.63 Million |
+11.10% |
| 2018-12-31 | ₩261.16 Billion ≈ $176.98 Million |
+13.48% |
| 2017-12-31 | ₩230.14 Billion ≈ $155.96 Million |
+12.20% |
| 2016-12-31 | ₩205.11 Billion ≈ $139.00 Million |
+11.32% |
| 2015-12-31 | ₩184.26 Billion ≈ $124.87 Million |
+6.82% |
| 2014-12-31 | ₩172.49 Billion ≈ $116.89 Million |
+11.01% |
| 2013-12-31 | ₩155.38 Billion ≈ $105.30 Million |
+27.28% |
| 2012-12-31 | ₩122.08 Billion ≈ $82.73 Million |
-- |
About Sam Chun Dang Pharm. Co. Ltd
Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea. It provides ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company was founded in 1943 and is headquartered in Seoul, S… Read more